11 – 20 of 166
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population-based study of 736 patients
(
- Contribution to journal › Article
- 2021
-
Mark
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
(
- Contribution to journal › Article
-
Mark
Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population-based Swedish chronic myeloid leukaemia registry
(
- Contribution to journal › Article
-
Mark
How should we use ibrutinib in patients with mantle cell lymphoma?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Parental origin of monosomy 7 in acute leukaemia
2021) In British Journal of Haematology(
- Contribution to journal › Letter
- 2020
-
Mark
Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century – a Swedish lymphoma register study
(
- Contribution to journal › Article
-
Mark
Monoclonal gammopathy of undetermined significance in medical hospital admissions – a new strategy for screening?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients
(
- Contribution to journal › Article
-
Mark
Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014 : improving performance status is a major contributing factor
(
- Contribution to journal › Letter
-
Mark
Frequent false-negative FIP1L1-PDGFRA FISH analyses of bone marrow samples from clonal eosinophilia at diagnosis
(
- Contribution to journal › Letter